CM
PTGX icon

Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2M Sell
124,800
-50,000
-29% -$4.43M 0.08% 276
2025
Q4 		$15.3M Buy
174,800
+156,800
+871% +$12.8M 0.1% 234
2025
Q3 		$1.2M Sell
18,000
-117,000
-87% -$6.65M 0.01% 1044
2025
Q2 		$7.46M Sell
135,000
-153,600
-53% -$7.37M 0.08% 287
2025
Q1 		$14M Buy
+288,600
New +$12.1M 0.13% 137
2023
Q3 		– Sell
-290,500
Closed -$8.02M – 1493
2023
Q2 		$8.02M Buy
290,500
+265,500
+1,062% +$6.64M 0.14% 177
2023
Q1 		$575K Buy
+25,000
New +$420K 0.01% 760
2022
Q3 		– Sell
-548,700
Closed -$4.34M – 1781
2022
Q2 		$4.34M Sell
548,700
-47,300
-8% -$572K 0.06% 404
2022
Q1 		$14.1M Buy
596,000
+579,100
+3,427% +$16.3M 0.17% 140
2021
Q4 		$577K Sell
16,900
-220,600
-93% -$6.97M 0.01% 1216
2021
Q3 		$4.21M Buy
+237,500
New +$10.1M 0.05% 523

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Caption Management's PTGX Position: Q1 2025 in Review

Caption Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 98,934 shares — an estimated $4.15M sold.

Caption Management first reported a position in PTGX in Q3 2021 and held it in 10 quarters. The position peaked at $6.59M in Q4 2021. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Caption Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 98,934 Protagonist Therapeutics shares in Q1 2025, an estimated $4.15M.
  • Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 10 quarters.
  • Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.